VERORAB

*Pre-exposure prophylaxis:* BY IM INJ: Adult & Children: 1 ml for 2 doses (on days 0 and 7), followed by 1 ml for 1 dose (on day 28), to be administered in deltoid region, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5 units/ml, final dose may be given from day 21, if insufficient time before travel. *Pre-exposure prophylaxis booster dose:* BY IM INJ: Adult & Children: 1 ml for 1 dose, to be given 1 year after primary course is completed, then 1 ml every 3-5 years, to be administered in deltoid region, the frequency of booster doses may alternatively be determined according to plasma concentration of antirabies antibodies; at infrequent risk of exposure booster dose may be given after 10 yrs. *Post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine):* BY IM INJ: Adult & Children: 1 ml for 1 dose, followed by 1 ml after 3-7 days for 1 dose, to be administered in deltoid region, rabies immunoglobulin is not necessary Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete):* BY IM INJ: Adult& Children: 1 ml 5 times amonth for 1 month, on days0, 3, 7, 14, and the fifth dose is given between day 28-30, to be administered in deltoid region, depending on the level of risk, rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunization course can be discontinued if it is proved that the individual was not at risk.

Pre-exposure prophylaxis in individuals with acute disorders or known allergy to components of the vaccine.

Congenital or acquired immunodeficiency, pregnancy (for post-exposure prophylaxis only), lactation, post-exposure immunization in patients with known-hypersensitivity to vaccine components. Inadvertent intravascular injection may lead to shock.

Immunosuppressive agents, antimalarial drugs.

Mild reactions at inj site, fever, headache, myalgia, lymph node swelling, fatigue, arthritis, GI disorders. Rarely: circulatory reactions, sweating, chills, paresthesia, allergic & neurological reactions